A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

James Biehl Biography and Net Worth

Insider of Tyme Technologies

James Biehl has served as our Chief Legal Officer and Secretary since September 2018 and served on our board of directors from 2017 until September 2018. Mr. Biehl has over 30 years of experience as a corporate and securities lawyer representing big pharma, healthcare systems, healthcare consulting firms, and consumer products and medical device companies. His entire career was with the law firm of Drinker Biddle & Reath LLP where he joined the firm in 1989 and was a partner for over 20 years. Mr. Biehl received a Bachelor of Science degree in Industrial Management from Carnegie Mellon University and a Juris Doctor degree from Temple University Beasley School of Law.

What is James Biehl's net worth?: The estimated net worth of James Biehl is at least $9,321.00 as of September 14th, 2023. Mr. Biehl owns 30,000 shares of Tyme Technologies stock worth more than $9,321 as of April 20th. This net worth estimate does not reflect any other investments that Mr. Biehl may own. Additionally, Mr. Biehl receives a salary of $635,890.00 as Insider at Tyme Technologies. Learn More about James Biehl's net worth.
How old is James Biehl?: Mr. Biehl is currently 58 years old. There are 4 older executives and no younger executives at Tyme Technologies. The oldest executive at Tyme Technologies is Dr. Jan Marie-Albert Van Tornout M.D., M.Sc., Acting Chief Medical Officer, who is 66 years old. Learn More on James Biehl's age.
What is James Biehl's salary?: As the Insider of Tyme Technologies, Inc., Mr. Biehl earns $635,890.00 per year. There are 2 executives that earn more than Mr. Biehl. The highest earning executive at Tyme Technologies is Mr. Steven E. Hoffman, Co-Founder & Director, who commands a salary of $2,600,000.00 per year. Learn More on James Biehl's salary.
How do I contact James Biehl?: The corporate mailing address for Mr. Biehl and other Tyme Technologies executives is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. Tyme Technologies can also be reached via phone at (212) 461-2315 and via email at [email protected]. Learn More on James Biehl's contact information.
Has James Biehl been buying or selling shares of Tyme Technologies?: James Biehl has not been actively trading shares of Tyme Technologies during the last ninety days. Most recently, on Thursday, December 23rd, James Biehl bought 10,000 shares of Tyme Technologies stock. The stock was acquired at an average cost of $0.65 per share, with a total value of $6,500.00. Learn More on James Biehl's trading history.
Who are Tyme Technologies' active insiders?: Tyme Technologies' insider roster includes James Biehl (Insider), David Carberry (Director), Michael Demurjian (Major Shareholder), Barbara Galaini (Insider), Steve Hoffman (Insider), and Jan Van Rornout (Insider). Learn More on Tyme Technologies' active insiders.

James Biehl Insider Trading History at Tyme Technologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/23/2021	Buy	10,000	$0.65	$6,500.00
9/1/2020	Buy	10,000	$0.95	$9,500.00	65,000

James Biehl Buying and Selling Activity at Tyme Technologies

Tyme Technologies Company Overview

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

Today's Range

Now: $0.31

$0.29

$0.32

50 Day Range

MA: $0.30

$0.24

$0.35

2 Week Range

Now: $0.31

$0.22

$1.14

Volume

2,678,186 shs

Average Volume

1,009,732 shs

Market Capitalization

$53.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad